Soluplus® promotes efficient transport of meloxicam to the central nervous system via nasal administration
Copyright © 2023 Elsevier B.V. All rights reserved..
In our present series of experiments, we investigated the nasal applicability of the previously developed Soluplus® - meloxicam polymeric micelle formulation. Utilizing the nasal drug investigations, moderately high mucoadhesion was experienced in nasal conditions which alongside the appropriate physicochemical properties in liquid state, contributed to rapid drug absorption through human RPMI 2650 cell line. Ex vivo studies also confirmed that higher nasal mucosal permeation could be expected with the polymeric micelle nanoformulation compared to a regular MEL suspension. Also, the nanoformulation met the requirements to provide rapid drug permeation in less 1 h of our measurement. The non-toxic, non-cell barrier damaging formulation also proved to provide a successful passive transport across excides human nasal mucosa. Based on our in vivo investigations, it can be concluded that the polymeric micelle formulation provides higher meloxicam transport to the central nervous system followed by a slow and long-lasting elimination process compared to prior results where physical particle size reduction methods were applied. With these results, a promising solution and nanocarrier is proposed for the successful transport of non-steroidal anti-inflammatory drugs with acidic character to the brain.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:632 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 632(2023) vom: 05. Feb., Seite 122594 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sipos, Bence [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brain |
|---|
| Anmerkungen: |
Date Completed 13.03.2023 Date Revised 13.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2023.122594 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351379932 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351379932 | ||
| 003 | DE-627 | ||
| 005 | 20231226051227.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2023.122594 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351379932 | ||
| 035 | |a (NLM)36626972 | ||
| 035 | |a (PII)S0378-5173(23)00014-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sipos, Bence |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Soluplus® promotes efficient transport of meloxicam to the central nervous system via nasal administration |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2023 | ||
| 500 | |a Date Revised 13.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a In our present series of experiments, we investigated the nasal applicability of the previously developed Soluplus® - meloxicam polymeric micelle formulation. Utilizing the nasal drug investigations, moderately high mucoadhesion was experienced in nasal conditions which alongside the appropriate physicochemical properties in liquid state, contributed to rapid drug absorption through human RPMI 2650 cell line. Ex vivo studies also confirmed that higher nasal mucosal permeation could be expected with the polymeric micelle nanoformulation compared to a regular MEL suspension. Also, the nanoformulation met the requirements to provide rapid drug permeation in less 1 h of our measurement. The non-toxic, non-cell barrier damaging formulation also proved to provide a successful passive transport across excides human nasal mucosa. Based on our in vivo investigations, it can be concluded that the polymeric micelle formulation provides higher meloxicam transport to the central nervous system followed by a slow and long-lasting elimination process compared to prior results where physical particle size reduction methods were applied. With these results, a promising solution and nanocarrier is proposed for the successful transport of non-steroidal anti-inflammatory drugs with acidic character to the brain | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Brain | |
| 650 | 4 | |a Meloxicam | |
| 650 | 4 | |a Nasal administration | |
| 650 | 4 | |a Permeability enhancement | |
| 650 | 4 | |a Polymeric micelle | |
| 650 | 7 | |a Meloxicam |2 NLM | |
| 650 | 7 | |a VG2QF83CGL |2 NLM | |
| 650 | 7 | |a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer |2 NLM | |
| 650 | 7 | |a Micelles |2 NLM | |
| 650 | 7 | |a Polymers |2 NLM | |
| 700 | 1 | |a Bella, Zsolt |e verfasserin |4 aut | |
| 700 | 1 | |a Gróf, Ilona |e verfasserin |4 aut | |
| 700 | 1 | |a Veszelka, Szilvia |e verfasserin |4 aut | |
| 700 | 1 | |a Deli, Mária A |e verfasserin |4 aut | |
| 700 | 1 | |a Szűcs, Kálmán F |e verfasserin |4 aut | |
| 700 | 1 | |a Sztojkov-Ivanov, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Ducza, Eszter |e verfasserin |4 aut | |
| 700 | 1 | |a Gáspár, Róbert |e verfasserin |4 aut | |
| 700 | 1 | |a Kecskeméti, Gábor |e verfasserin |4 aut | |
| 700 | 1 | |a Janáky, Tamás |e verfasserin |4 aut | |
| 700 | 1 | |a Volk, Balázs |e verfasserin |4 aut | |
| 700 | 1 | |a Budai-Szűcs, Mária |e verfasserin |4 aut | |
| 700 | 1 | |a Ambrus, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Szabó-Révész, Piroska |e verfasserin |4 aut | |
| 700 | 1 | |a Csóka, Ildikó |e verfasserin |4 aut | |
| 700 | 1 | |a Katona, Gábor |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 632(2023) vom: 05. Feb., Seite 122594 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:632 |g year:2023 |g day:05 |g month:02 |g pages:122594 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2023.122594 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 632 |j 2023 |b 05 |c 02 |h 122594 | ||